Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Overview

NYSE:ANRO - US02157Q1094 - Common Stock

4.15 USD
+0.21 (+5.33%)
Last: 8/26/2025, 8:14:59 PM
4.05 USD
-0.1 (-2.41%)
After Hours: 8/26/2025, 8:14:59 PM

ANRO Key Statistics, Chart & Performance

Key Statistics
52 Week High15.04
52 Week Low1.6
Market Cap112.38M
Shares27.08M
Float24.80M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.39
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/amc
IPO02-02 2024-02-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ANRO short term performance overview.The bars show the price performance of ANRO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

ANRO long term performance overview.The bars show the price performance of ANRO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ANRO is 4.15 USD. In the past month the price increased by 36.07%. In the past year, price decreased by -67.6%.

ALTO NEUROSCIENCE INC / ANRO Daily stock chart

ANRO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.57 696.62B
JNJ JOHNSON & JOHNSON 17.65 425.05B
AZN ASTRAZENECA PLC-SPONS ADR 18.03 248.19B
NVO NOVO-NORDISK A/S-SPONS ADR 14.19 245.90B
NVS NOVARTIS AG-SPONSORED ADR 14.31 245.16B
MRK MERCK & CO. INC. 11.04 212.29B
PFE PFIZER INC 7.35 141.68B
SNY SANOFI-ADR 11.38 122.68B
BMY BRISTOL-MYERS SQUIBB CO 7.01 96.09B
GSK GSK PLC-SPON ADR 8.81 80.29B
ZTS ZOETIS INC 24.89 68.60B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.6 46.99B

About ANRO

Company Profile

ANRO logo image Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The company went IPO on 2024-02-02. The firm is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. The advanced programs are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.

Company Info

ALTO NEUROSCIENCE INC

650 Castro Street, Suite 450

Mountain View CALIFORNIA US

Employees: 76

ANRO Company Website

ANRO Investor Relations

Phone: 17732555012

ALTO NEUROSCIENCE INC / ANRO FAQ

What is the stock price of ALTO NEUROSCIENCE INC today?

The current stock price of ANRO is 4.15 USD. The price increased by 5.33% in the last trading session.


What is the ticker symbol for ALTO NEUROSCIENCE INC stock?

The exchange symbol of ALTO NEUROSCIENCE INC is ANRO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is ANRO stock listed?

ANRO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for ALTO NEUROSCIENCE INC stock?

14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 153.98% is expected in the next year compared to the current price of 4.15. Check the ALTO NEUROSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALTO NEUROSCIENCE INC worth?

ALTO NEUROSCIENCE INC (ANRO) has a market capitalization of 112.38M USD. This makes ANRO a Micro Cap stock.


How many employees does ALTO NEUROSCIENCE INC have?

ALTO NEUROSCIENCE INC (ANRO) currently has 76 employees.


What are the support and resistance levels for ALTO NEUROSCIENCE INC (ANRO) stock?

ALTO NEUROSCIENCE INC (ANRO) has a support level at 2.66. Check the full technical report for a detailed analysis of ANRO support and resistance levels.


Should I buy ALTO NEUROSCIENCE INC (ANRO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALTO NEUROSCIENCE INC (ANRO) stock pay dividends?

ANRO does not pay a dividend.


When does ALTO NEUROSCIENCE INC (ANRO) report earnings?

ALTO NEUROSCIENCE INC (ANRO) will report earnings on 2025-11-12, after the market close.


What is the Price/Earnings (PE) ratio of ALTO NEUROSCIENCE INC (ANRO)?

ALTO NEUROSCIENCE INC (ANRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).


What is the Short Interest ratio of ALTO NEUROSCIENCE INC (ANRO) stock?

The outstanding short interest for ALTO NEUROSCIENCE INC (ANRO) is 8.66% of its float. Check the ownership tab for more information on the ANRO short interest.


ANRO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ANRO. When comparing the yearly performance of all stocks, ANRO is a bad performer in the overall market: 75.64% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ANRO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ANRO. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANRO Financial Highlights

Over the last trailing twelve months ANRO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -75.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.75%
ROE -45.42%
Debt/Equity 0.15
Chartmill High Growth Momentum
EPS Q2Q%-8.33%
Sales Q2Q%N/A
EPS 1Y (TTM)-75.89%
Revenue 1Y (TTM)N/A

ANRO Forecast & Estimates

14 analysts have analysed ANRO and the average price target is 10.54 USD. This implies a price increase of 153.98% is expected in the next year compared to the current price of 4.15.


Analysts
Analysts85.71
Price Target10.54 (153.98%)
EPS Next Y-3.78%
Revenue Next YearN/A

ANRO Ownership

Ownership
Inst Owners77.46%
Ins Owners7.48%
Short Float %8.66%
Short Ratio9.55